Brain RAAS could represent a new important therapeutic target to regulate cardiovascular and neurological diseases. Aminopeptidase type A inhibitors and angiotensin IV analogues are new drug classes acting on the brain RAAS. The development of compounds able to cross the blood-brain barrier is challenging due to the pharmacokinetic characteristics.